We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Vaginal Biomarkers Predict Preterm Birth Risks

By LabMedica International staff writers
Posted on 04 Nov 2019
Print article
Image: The DuoSet ELISA kit for determining levels of MMP-3 and TIMP-1 (Photo courtesy of R&D Systems).
Image: The DuoSet ELISA kit for determining levels of MMP-3 and TIMP-1 (Photo courtesy of R&D Systems).
Premature birth and its complications are the largest contributors to infant death in the USA and globally. Complications of preterm birth are the single largest cause of neonatal deaths and account for 35% of the world’s 3.1 million neonatal deaths each year.

A short cervical length and the depletion of Lactobacillus species are known risk factors for preterm birth. In many resource-poor areas of the world, the technology to test for the occurrence of these risk factors is unavailable, and pregnant women with specific risk factors are neither identified nor treated.

An international team of scientists working with the University of Idaho (Moscow, ID, USA) collected and analyzed vaginal fluid samples from 340 mid-trimester pregnant women to determine correlates of a short cervix. They carried out a prospective study of these women who were undergoing a routine vaginal ultrasound to assess cervical length at the obstetrical outpatient clinic at The Federal University of Sao Paulo (Sao Paulo, Brazil).

Vaginal levels of the D- and L-lactic acid isomers were quantitated by colorimetric assays using the EnzyChrom D-lactic acid and L-lactic acid kits (BioAssay Systems, Haywood, CA, USA). The levels of TIMP-1, TIMP-2, MMP-2, MMP-8, and Hsp70 (all from R&D Systems, Minneapolis, MN, USA) and total protein (Thermo-Fisher Scientific, Waltham, MA, USA) were measured in the vaginal fluid supernatant. The p62 (Enzo Life Sciences, Farmingdale, NY, USA), the a2 isoform of vacuolar ATPase (a2V) (MyBioSource, San Diego, CA, USA), and total protein in the lysed epithelial cell fraction were determined by commercial enzyme-linked immunosorbent assay (ELISA) kits. The compositions of vaginal microbiomes were assessed by analysis of the V1-V3 regions of 16S rRNA genes, while cervical length was determined by transvaginal ultrasonography.

The scientists reported that the vaginal microbiomes could be clustered into five community state types (CSTs), four of which were dominated by a single Lactobacillus species. The dominance of Lactobacillus crispatus or Lactobacillus jensenii in the vaginal microbiome predicted the level of D-lactic acid present. Several of the biomarkers, especially TIMP-1, in combination with the subject’s age and race, were significantly associated with cervical length.

Larry Forney, PhD, a professor and senior author of the study, said, “Measuring levels of TIMP-1 and D-lactic acid in vaginal secretions might be a straightforward way to assess a woman's risk for preterm birth. This is a prime example of the kind of study that can be done when you bring people in from different disciplines. This team of investigators included obstetricians, gynecologists, immunologists, microbial ecologists, and statisticians.

The authors concluded that concluded that measuring levels of TIMP-1 and D-lactic acid in vaginal secretions might be a straightforward way to assess the risk for preterm birth due to a short cervix and microbiome composition. The study was published on October 22, 2019, in the journal mBio.

Related Links:
University of Idaho
The Federal University of Sao Paulo
R&D Systems
BioAssay Systems
Thermo-Fisher Scientific
Enzo Life Sciences
MyBioSource


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.